Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-20 02:02 UTC

BIOMED PULSE

Friday, June 20, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo Ebola outbreak in DRC and Uganda has reached 896 confirmed cases and 232 deaths as of June 17, making it the dominant global health emergency right now. [1] The mood is grim on outbreak control but cautiously active on treatment discovery, with WHO experts now formally assessing candidate vaccines and therapeutics for Bundibugyo virus. [2]

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA: PHEIC DECLARED

  • As of June 17, 2026, a cumulative 896 confirmed cases and 232 confirmed deaths have been reported from the DRC, with cross-border transmission continuing into Uganda. [1]
  • WHO declared the Bundibugyo virus disease (BVD) outbreak a Public Health Emergency of International Concern (PHEIC) on May 16-17, 2026, noting it does not yet meet the threshold for a pandemic emergency. [3] [4]
  • Africa CDC and WHO jointly launched a continental preparedness and response plan on June 5, 2026, aiming to raise US$518 million to support African countries in containing BVD spread. [5]
  • WHO convened expert advisory groups on May 28, 2026, to assess candidate vaccines and therapeutics specifically for Bundibugyo virus, as existing Ebola tools were developed primarily against Zaire virus. [2]
  • CDC mobilized an international Ebola response on May 17, 2026, and activated enhanced airport screening at Washington-Dulles International Airport and Atlanta Hartsfield-Jackson to intercept travelers arriving from affected regions. [6] [7]
  • A CDC briefing on June 18, 2026, combined the Ebola outbreak update with activation of CDC's World Cup 2026 health protocols, reflecting concern about mass-gathering transmission risk. [8]

HANTAVIRUS - M/V HONDIUS CRUISE SHIP: MULTI-COUNTRY

  • The Andes hantavirus outbreak linked to cruise ship M/V Hondius has resulted in a total of 10 confirmed or probable cases across multiple countries as of the fourth WHO Disease Outbreak News report published May 28, 2026. [9]
  • The original cluster began May 2, 2026, with severe respiratory illness among 147 passengers and crew; WHO confirmed the involved strain is Andes hantavirus, which is notable for its documented rare human-to-human transmission capacity. [10]
  • CDC provided multiple response updates through mid-May and confirmed the U.S. government assessed public risk to the American general population as extremely low.
  • Over 120 passengers from 23 countries were safely disembarked at Tenerife, Spain, following a coordinated international health operation praised by WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

MPOX - GLOBAL SITUATION

  • WHO's December 2025 Disease Outbreak News documented local transmission of clade Ib MPXV among men who have sex with men in countries previously reporting only travel-linked cases, signaling broadening community spread beyond the original central African epicenter.
  • A separate February 2026 WHO report confirmed two documented cases of a recombinant MPXV strain combining genetic elements of clade Ib and clade IIb, a naturally occurring but epidemiologically significant genomic event.

NIPAH VIRUS - INDIA AND BANGLADESH

  • India notified WHO on January 26, 2026, of two laboratory-confirmed Nipah virus infections in healthcare workers at a private hospital in Barasat, North 24 Parganas district, West Bengal; both were confirmed at the National Institute of Virology, Pune.
  • Bangladesh separately reported one confirmed Nipah case in Rajshahi Division on February 3, 2026, with the patient developing fever and neurological symptoms on January 21, 2026.

SALMONELLA - MULTIPLE ACTIVE OUTBREAKS

  • CDC warned on June 16, 2026, of a new Salmonella outbreak linked to pistachio cream, with four people ill from the same strain.
  • A Salmonella outbreak linked to backyard poultry active since April 2026 had sickened 34 people across 13 states as of April 23, expanding to 150-plus additional people by May 14, with over one quarter of cases in children under age 5.
  • Extensively drug-resistant Salmonella linked to moringa powder capsules has been a persistent CDC concern since late 2025, with 65 people in 28 states reported as of January 29, 2026, and alerts still active through May 2026.

LISTERIA - CHICKEN FETTUCCINE ALFREDO MEALS

  • CDC warned on June 19, 2026 of a Listeria outbreak linked to recalled chicken fettuccine alfredo meals, with 17 people sick from the same Listeria strain.
  • A separate Listeria outbreak linked to requesón and soft ricotta cheese was flagged by CDC on June 5, 2026.

NEW WORLD SCREWWORM - EMERGENCY OPERATIONS

  • CDC activated its Emergency Operations Center on June 12, 2026, for a New World Screwworm response, a parasitic fly whose larvae infest living tissue and which has not been an established U.S. public health threat in recent decades.

MERS-COV - GLOBAL UPDATE

  • As of December 21, 2025, a total of 19 MERS-CoV cases including four deaths were reported to WHO globally in 2025; 17 originated in Saudi Arabia and two in France, with no evidence of sustained community transmission.

INFANT BOTULISM - FORMULA RECALL

  • CDC on June 13, 2026, urged parents to immediately stop using Nara Organics Whole Milk Organic Infant Formula, citing an ongoing infant botulism outbreak linked to the product.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE - POLYAMINE METABOLISM AND KIDNEY REPAIR

  • A June 14, 2026, Europe PMC study (Ren Fail) found that AMD1-mediated polyamine metabolism governs whether kidney tubular cells undergo repair or enter irreversible senescence after acute kidney injury, identifying a potential metabolic target to prevent organ aging after damage.

BIOLOGICAL AGING CLOCKS - DNA METHYLATION AND INTRACRANIAL ANEURYSM RISK

  • A mendelian randomization study (IBRO Neurosci Rep, May 30, 2026) linked DNA methylation-estimated biological age acceleration and shorter telomere length to increased risk of intracranial aneurysms, reinforcing the concept that epigenetic aging markers predict structural vascular vulnerability beyond chronological age.

COLLAGEN OXIDATION - EXTRACELLULAR MATRIX AGING

  • Research published in Redox Rep (June 11, 2026) detailed how both enzymatic and non-enzymatic oxidation of fibrillar collagen degrades extracellular matrix integrity, a mechanism central to skin aging, joint deterioration, and vascular stiffening with age.

ALBUMIN REDOX STATUS - AGING BIOMARKER

  • A Europe PMC study (Redox Rep, June 2, 2026) characterized oxidation of cysteine-34 on albumin as a measurable biomarker of systemic redox stress, with polysulfide-mediated homeostatic mechanisms identified as a counterbalancing protective pathway relevant to aging physiology.

GUT MICROBIOME - MATERNAL DIET AND NEONATAL NEUROMETABOLIC RESILIENCE

  • A June 9, 2026, Gut Microbes study (Kadyan et al.) showed that maternal diet shapes the neonatal gut microbiome's development and influences neurometabolic resilience, suggesting early-life microbiome programming has consequences for long-term metabolic and brain aging trajectories.

PREBIOTICS - PHYSICAL FUNCTION IN OLDER ADULTS WITH OBESITY AND KNEE OSTEOARTHRITIS

  • A multi-omics study in Gut Microbes (June 2, 2026, Wang et al.) found prebiotic supplementation modulated physical function and metabolism in older adults with obesity and knee osteoarthritis, with changes observed in gut microbiota composition, lipid metabolism, and inflammatory markers.

GRIP STRENGTH - CHRONIC DIGESTIVE DISEASE INCIDENCE IN OLDER ADULTS

  • A prospective parallel cohort analysis (Glob Health Action, June 15, 2026, Liu et al.) found lower combined handgrip strength in older adults was independently associated with incident chronic digestive diseases in both Chinese and European populations, reinforcing handgrip as a simple proxy for systemic biological aging and organ vulnerability.

REPRODUCTIVE AGING - DELAYED CHILDBEARING REVIEW

  • A narrative review in J Obstet Gynaecol (June 9, 2026, Yang et al.) examined the mechanisms by which delayed childbearing accelerates reproductive aging, including declining oocyte quality, ovarian reserve depletion, and epigenetic changes, noting increasing societal relevance as first-birth age rises globally.

URIC ACID AND FERROPTOSIS - PARKINSON'S DISEASE MODEL

  • A June 4, 2026, Redox Rep study found uric acid reduced neuroinflammation and protected against ferroptosis (iron-dependent cell death) in both LPS-induced BV2 cell models and MPTP-induced Parkinson's disease mouse models via the Nrf2 signaling pathway, suggesting a potential neuroprotective mechanism relevant to age-related neurodegeneration.

DELIRIUM - MISSED HOSPITAL RECOGNITION

  • A hospital records audit published in Int J Nurs Stud Adv (May 25, 2026) found delirium in older hospitalized patients was frequently documented with euphemistic language such as "pleasantly confused," leading to systematic missed diagnoses and delayed treatment, with significant implications for older adult outcomes and cognitive trajectory.

💊 NEW CURES & APPROVALS

PEMBROLIZUMAB (KEYTRUDA) - MERCK SHARP DOHME

  • Merck Sharp Dohme received a supplemental approval (SUPPL AP) for pembrolizumab (Keytruda, BLA125514), an anti-PD-1 immune checkpoint inhibitor used across multiple oncology indications; the specific supplemental indication detail is listed as pending in the FDA record.

RISANKIZUMAB-RZAA (SKYRIZI) - ABBVIE INC

  • AbbVie received two separate supplemental approvals for risankizumab-rzaa (Skyrizi), an IL-23 inhibitor, under BLA761262 and BLA761105, reflecting the drug's expanding use across inflammatory conditions including Crohn's disease, ulcerative colitis, and plaque psoriasis.

BELZUTIFAN (WELIREG) - MERCK SHARP DOHME

  • Merck Sharp Dohme received a supplemental approval for belzutifan (Welireg, NDA215383), a HIF-2 alpha inhibitor approved for cancers associated with von Hippel-Lindau disease and now expanding its oncology label.

CAPIVASERTIB (TRUQAP) - ASTRAZENECA

  • AstraZeneca received a supplemental approval for capivasertib (Truqap, NDA218197), an AKT kinase inhibitor used in combination for hormone receptor-positive, HER2-negative breast cancer with PIK3CA, AKT1, or PTEN alterations.

IPILIMUMAB (YERVOY) - BRISTOL MYERS SQUIBB

  • Bristol Myers Squibb received a supplemental approval for ipilimumab (Yervoy, BLA125377), a CTLA-4 immune checkpoint inhibitor, continuing expansion of its combination immunotherapy use in oncology.

UPADACITINIB LIQUID (RINVOQ LQ) - ABBVIE

  • AbbVie received a supplemental approval for upadacitinib liquid formulation (Rinvoq LQ, NDA218347), a JAK1 inhibitor; the liquid formulation expands administration options for inflammatory conditions including juvenile idiopathic arthritis and atopic dermatitis.

TEPLIZUMAB-MZWV (TZIELD) - PROVENTION BIO INC

  • Provention Bio received a supplemental approval for teplizumab-mzwv (Tzield, BLA761183), a CD3-directed antibody that delays the onset of clinical type 1 diabetes in at-risk individuals by partially preserving beta-cell function.

NALOXONE HYDROCHLORIDE (REXTOVY) - AMPHASTAR PHARMACEUTICALS

  • Amphastar Pharmaceuticals received a supplemental approval for naloxone hydrochloride (Rextovy, NDA208969), an opioid antagonist used for rapid reversal of opioid overdose.

PERAMPANEL - TARO PHARMACEUTICALS (GENERIC)

  • Taro Pharmaceuticals received an original approval (ORIG AP) for a generic perampanel (ANDA219052), an AMPA-type glutamate receptor antagonist used as adjunctive therapy for epileptic seizures.

LACOSAMIDE - PROD DEVELOPMENT (GENERIC)

  • A generic lacosamide (ANDA217596) received an original approval; lacosamide enhances slow inactivation of voltage-gated sodium channels and is used for focal-onset seizures.

🧪 CLINICAL TRIALS

MAP-HEART - HEART FAILURE MULTI-SCALE PHENOTYPING

  • The MAP-HEART study (NCT06280820, registered June 18, 2026) is collecting blood and tissue samples from the more than 6.5 million U.S. adults living with heart failure to build a multi-scale biological picture of how the disease develops across aging phenotypes.

AI-BASED COGNITIVE ASSESSMENT IN OLDER ADULTS - VR DRIVING TASKS

  • A trial registered June 18, 2026 (NCT07656389) is using AI to predict cognitive capacity in older adults and individuals with mild cognitive impairment during virtual reality driving simulations, targeting the "look-but-fail-to-see" attention failure pattern associated with crash risk in aging drivers.

VIRTUAL REALITY FOR GAIT AND BALANCE - OLDER ADULTS

  • NCT07655882 (registered June 18, 2026) is a randomized study comparing VR-based interactive exercise training against traditional physical therapy for improving walking and balance in older adults, addressing fall risk as a primary aging-related outcome.

TARGETED TEMPERATURE MANAGEMENT - NEUROCOGNITIVE RECOVERY IN OLDER CANCER SURGICAL PATIENTS

  • NCT07655687 (registered June 18, 2026) is investigating whether targeted temperature management during major cancer surgery in older patients can reduce delayed neurocognitive recovery, a complication associated with prolonged hospital stay and increased mortality in aging surgical populations.

SIROLIMUS FOR SLE-ASSOCIATED IMMUNE THROMBOCYTOPENIA

  • NCT07657793 (registered June 18, 2026) is testing sirolimus, an mTOR inhibitor with known longevity-relevant mechanisms, added to standard corticosteroid and hydroxychloroquine therapy in adults aged 18-65 with systemic lupus erythematosus-associated immune thrombocytopenia.

DUPILUMAB FOR BULLOUS PEMPHIGOID

  • NCT04206553 is evaluating dupilumab, a monoclonal antibody blocking IL-4 and IL-13 signaling, for bullous pemphigoid, an autoimmune blistering disease that disproportionately affects older adults and is associated with accelerated mortality in the elderly.

ORFORGLIPRON (LY3502970) IN ADOLESCENTS WITH OBESITY

  • NCT06672939, sponsored under Eli Lilly's master protocol NCT06672549, is testing the oral GLP-1 receptor agonist orforglipron once daily in adolescents with obesity or overweight with comorbidities, evaluating efficacy, safety, and pharmacokinetics in a younger population as obesity increasingly tracks into aging-related metabolic disease.

LOSARTAN FOR RADIATION-INDUCED FIBROSIS IN BREAST CANCER

  • NCT05637216 is evaluating losartan, an FDA-approved TGF-beta-1 blocker (AT1 receptor antagonist), to reduce radiation-induced fibrosis in breast and lung tissue after breast cancer radiotherapy, targeting a senescence-associated fibrotic mechanism.

PANCREAS LIPOTOXICITY AND TYPE 2 DIABETES REMISSION - EDINBURGH DIABETES REMISSION STUDY

  • The EDRS (NCT07364045, registered June 18, 2026) is investigating how intrapancreatic fat accumulation drives type 2 diabetes and whether weight-loss-induced fat reduction can reverse beta-cell dysfunction, extending prior research showing that metabolic remission accompanies structural pancreatic changes.

📢 PUBLIC HEALTH

ACIP MEETING - JUNE 25-26, 2025

  • CDC's Advisory Committee on Immunization Practices will meet June 25-26, 2025, to review vaccine data; a joint statement was subsequently released confirming conclusions of the two-day session, details of which are published online per CDC.

FOOD SAFETY - LISTERIA AND SALMONELLA ACTIVE ALERTS

  • As of June 19, 2026, consumers are warned to avoid recalled chicken fettuccine alfredo meals linked to a 17-person Listeria outbreak, and to check refrigerators for any recalled requesón or soft ricotta cheese flagged June 5, 2026.
  • Pistachio cream is the newest Salmonella-linked product as of June 16, 2026, affecting four people; consumers should avoid any pistachio cream products under investigation.

WHO PANDEMIC AGREEMENT - PATHOGEN ACCESS AND BENEFIT SHARING

  • On June 15, 2026, WHO Director-General Dr. Tedros and partners published an open letter to leaders of G7, G20, BRICS, and all nations urging finalization of the Pathogen Access and Benefit Sharing (PABS) annex to the WHO Pandemic Agreement, framing it as essential infrastructure to ensure equitable access to vaccines and treatments in future outbreaks.

WHO - GLOBAL HEALTH STATISTICS 2026

  • The WHO World Health Statistics 2026 report, published May 13, 2026, warned that progress on global health targets is uneven, slowing, and in some areas reversing, representing a systemic threat to life-expectancy gains made over prior decades.

UNSAFE FOOD - GLOBAL BURDEN UPDATE

  • WHO released estimates on June 3-4, 2026, calculating that unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide, with children under age five facing almost three times the risk of foodborne illness compared with older children and adults.

CDC BIOSURVEILLANCE - ONE MILLION AIR TRAVELERS ENROLLED

  • CDC announced January 30, 2026, that its Traveler-Based Genomic Surveillance program surpassed one million voluntary participants, strengthening the agency's capacity to detect novel and emerging pathogens at points of entry.

DRUG-RESISTANT BACTERIA - SHARP CDC-REPORTED RISE

  • A CDC report published September 23, 2025, found a dramatic increase in dangerous drug-resistant bacteria, underscoring antimicrobial resistance as an accelerating threat to treatment options across all age groups.

This briefing is informational only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  3. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  4. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. Transcript - Update on Ebola Outbreak in the Democratic Republic of the Congo and Uganda and CDC's World Cup 2026(TM) ac — CDC Newsroom
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260620-02-v6 · 2026-06-20 02:02 UTC

Read next